FUJIFILM VisualSonics Introduces Vevo LAZR-X

FUJIFILM VisualSonics Inc., a developer of ultra high frequency ultrasound and photoacoustic imaging systems and subsidiary of FUJIFILM SonoSite, Inc., has announced the launch of its new Vevo LAZR-X, the world’s only customizable imaging platform combining ultra high frequency ultrasound and photoacoustics for animal research applications. Featuring superior image resolution—down to 30 microns—the Vevo LAZR-X was designed for a variety of translational research applications including oncology, molecular biology, cardiology and neurobiology.
 
“Fujifilm VisualSonics is proud to debut another industry-first and a powerful innovation for today’s busy researchers,” said Diku Mandavia, M.D., FACEP, FRCPC, chief medical officer and senior vice president, FUJIFILM SonoSite Inc. and FUJIFILM Medical Systems U.S.A. Inc. “Our Vevo technology is already used in hundreds of research laboratories. The new Vevo LAZR-X takes it to the next level, providing the ultimate preclinical imaging experience through a dual tool comprised of ultra high frequency ultrasound and advanced photoacoustic technology.”
 
Offering a fusion of anatomical, functional and molecular data, Vevo LAZR-X was designed for non-invasive, real-time, longitudinal studies. The all-in-one imaging platform puts more data at the users’ fingertips and is equipped with an array of software applications that allow researchers to conduct in-depth analysis and rapid quantification to advance research and get published faster.
 
A portable, customizable system, Vevo LAZR-X pairs Fujifilm VisualSonics’ Vevo 3100 ultrasound system, which provides unparalleled resolution, with the compact LAZR-X cart featuring advanced laser technology for fast, sensitive acquisition along with dual wavelength ranges including signal (680-970 nm) and idler (1200-2000 nm). High-resolution MX linear array transducers can be paired with interchangeable, high-efficiency optical fibers—giving researchers the ability to customize depth, sensitivity and resolution for specific imaging needs. Other features include streamlined data management, an intuitive touchscreen interface, ergonomically-designed transducers, and a unique open imaging environment that allows the researcher to access and manipulate the subject animal during the scanning process.
 
“At Fujifilm VisualSonics our purpose is to boldly innovate new technologies that help scientists and researchers advance human health. Our new Vevo LAZR-X platform is a great example of this continual innovation. It is designed with flexibility in mind, allowing for application-specific imaging to collect robust data for exceptional translational research,” said Andrew Needles, director of marketing and product management, FUJIFILM VisualSonics Inc.
 
The Vevo LAZR-X is available worldwide.
 
FUJIFILM VisualSonics Inc. develops real time, in vivo, ultra high frequency ultrasound and photoacoustic imaging systems. With headquarters in Toronto, Canada, and offices around the world, FUJIFILM VisualSonics is recognized for providing imaging technologies for the advancement of preclinical research, particularly in cardiovascular, oncology, neurobiology and developmental biology areas. With the expansion of the product portfolio to include a new clinical product, FUJIFILM VisualSonics now broadens its range of imaging technologies across both preclinical and clinical markets. FUJIFILM VisualSonics is a subsidiary of FUJIFILM SonoSite Inc. and a part of FUJIFILM Holdings Corporation.

FUJIFILM SonoSite Inc. develops bedside and point-of-care ultrasound, and ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, Wash., the company is represented by 26 subsidiaries and a global distribution network in more than 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care.
 
FUJIFILM Holdings Corporation of Tokyo, Japan, develops products in various industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2016, the company had global revenues of $22.1 billion, at an exchange rate of 112.54 yen to the dollar.